Cyto-Mine® addresses the time-consuming, labor-intensive nature of screening large cell populations for rare antigen-specific, antibody-secreting cells during antibody discovery by streamlining the traditional multi-step process into one seamless, fully-integrated one-day workflow.

The rise in monoclonal antibody-based therapeutics over the past 20 years has been extraordinary with over 80 mAbs now approved for use. With antibody-based therapeutics entering clinical studies and being approved faster than ever before their success, and increasing competition, is creating a large demand on biopharmaceutical companies to reduce the time it takes to bring new biologics to market. Download to continue reading…